medigraphic.com
Colegio de Medicina Interna de México.

2011, Número 6

Med Int Mex 2011; 27 (6)


Asociación de la proteína C reactiva con la respuesta al tratamiento antimicrobiano en adultos mayores con neumonía adquirida en la comunidad

Montes DG, Rivero NMÁ, Mendieta ZH

Idioma: Español
Referencias bibliográficas: 33
Paginas: 517-526
Archivo PDF: 254.03 Kb.


RESUMEN

Antecedentes: existen estudios de la utilidad de la proteína C reactiva en el diagnóstico y como factor pronóstico de neumonía adquirida en la comunidad, pero pocos en pacientes geriátricos.
Objetivo: determinar la asociación de las concentraciones séricas de proteína C reactiva con la respuesta al tratamiento antimicrobiano en el paciente adulto mayor con neumonía adquirida en la comunidad.
Pacientes y método: estudio de cohorte, prospectivo, efectuado en el servicio de Geriatría del Centro Médico ISSEMYM, Toluca, Estado de México. Las concentraciones séricas de proteína C reactiva se determinaron mediante inmunoturbidimetría (Roche, modelo Hitachi 9l7).
Resultados: se estudiaron 19 pacientes con edad promedio de 80 ± 5.6 años, con límites de 71 y 91 años, con promedio de seguimiento de 10 ± 2 días (límites 7 y 15), su distribución fue de 12 hombres (63%) y 7 mujeres (37%). Por análisis multivariado se encontró que los sujetos que permanecieron con concentraciones séricas de proteína C reactiva superiores a 10 mg/dL al terminar el tratamiento tuvieron un riesgo relativo de 1.5 (IC 95%, 0.67-3.33; p= 0.158) de tener una evolución tórpida de su cuadro neumónico.
Conclusiones: la concentración sérica de proteína C reactiva mayor de 10 mg/dL es indicadora de gravedad para neumonía adquirida en la comunidad.

REFERENCIAS (EN ESTE ARTÍCULO)

  1. Loeb M. Pneumonia in the elderly. Curr Opin Infect Dis 2004;17:127-130.

  2. Kaplan V, Angus DC. Community-acquired pneumonia in the elderly. Crit Care Clin 2003;19:729-748.

  3. Fernández-Sabe N, Carratala J, Roson B, Dorca J, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003;82:159-169.

  4. Niederman MS, Ahmed QA. Community-acquired pneumonia in elderly patients. Clin Geriatr Med 2003;19:101-120.

  5. Feldman C. Pneumonia in the elderly. Med Clin North Am 2001;85:1441-159.

  6. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000;31:1066-1078.

  7. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Am Fam Physician 2001;63:257-268.

  8. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003;21:294-302.

  9. Alves DW, Kennedy MT. Community-acquired pneumonia in casualty: etiology, clinical features, diagnosis, and management (or a look at the "new" in pneumonia since 2002). Curr Opin Pulm Med 2004;10:166-170.

  10. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163:645-651.

  11. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001.

  12. Thibodeau KP, Viera AJ. Atypical pathogens and challenges in community-acquired pneumonia. Am Fam Physician 2004;69:1699-1706.

  13. Furman CD, Rayner AV, Tobin EP. Pneumonia in older residents of long-term care facilities. Am Fam Physician 2004;70:1495-1500.

  14. Polverino E, Torres MA. Community-acquired pneumonia. Minerva Anestesiol 2011;77:196-211.

  15. Farah R, Makhoul N. Usefulness of various inflammatory markers to differentiate pulmonary edema from pneumonia. Isr Med Assoc J 2011;13:225-229.

  16. Arinzon Z, Peisakh A, Schrire S, Berner Y. C-reactive protein (CRP): An important diagnostic and prognostic tool in nursing-home-associated pneumonia. Arch Gerontol Geriatr 2011.

  17. Smith RP, Lipworth BJ. C-reactive protein in simple communityacquired pneumonia. Chest 1995;107:1028-1031.

  18. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in followup of severe community-acquired pneumonia. Eur Respir J 2008;32:726-732.

  19. Requejo HI, Cocoza AM. C-reactive protein in the diagnosis of community-acquired pneumonia. Braz J Infect Dis 2003;7:241-244.

  20. Summah H, Qu JM. Biomarkers: a definite plus in pneumonia. Mediators Inflamm 2009;2009:675-753.

  21. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003;123:2043-2049.

  22. Almirall J, Bolibar I, Toran P, Pera G, et al. Contribution of Creactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335-1342.

  23. Garcia VE, Martinez JA, Mensa J, Sanchez F, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003;21:702-705.

  24. Flanders SA, Stein J, Shochat G, Sellers K, et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004;116:529-535.

  25. 25 Reny JL, Vuagnat A, Ract C, Benoit MO, et al. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med 2002;30:529-535.

  26. 26 Coelho L, Povoa P, Almeida E, Fernandes A, et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007;11:R92.

  27. Kaplan V, Angus DC, Griffin MF, Clermont G, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002;165:766-772.

  28. Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, et al. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003;53:358-364.

  29. Seppa Y, Bloigu A, Honkanen PO, Miettinen L, Syrjala H. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Arch Intern Med 2001;161:2709-2713.

  30. Melbye H, Stocks N. Point of care testing for C-reactive protein - a new path for Australian GPs? Aust Fam Physician 2006;35:513-517.

  31. Lauritzen B, Lykkesfeldt J, Skaanild MT, Angen O, et al. Putative biomarkers for evaluating antibiotic treatment: an experimental model of porcine Actinobacillus pleuropneumoniae infection. Res Vet Sci 2003;74:261-270.

  32. Povoa P, Coelho L, Almeida E, Fernandes A, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005;11:101-108.

  33. Van der Meer, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ 2005;331:26.




2020     |     www.medigraphic.com